- Home
- ACRS vs GENC Comparison
ACRS vs GENC Comparison
Compare ACRS & GENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- GENC
- Stock Information
- Founded
- ACRS 2012
- GENC 1894
- Country
- ACRS United States
- GENC United States
- Employees
- ACRS N/A
- GENC N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- GENC Construction/Ag Equipment/Trucks
- Sector
- ACRS Health Care
- GENC Industrials
- Exchange
- ACRS Nasdaq
- GENC Nasdaq
- Market Cap
- ACRS 170.9M
- GENC 181.9M
- IPO Year
- ACRS 2015
- GENC N/A
- Fundamental
- Price
- ACRS $1.53
- GENC $11.88
- Analyst Decision
- ACRS Strong Buy
- GENC
- Analyst Count
- ACRS 7
- GENC 0
- Target Price
- ACRS $11.67
- GENC N/A
- AVG Volume (30 Days)
- ACRS 1.2M
- GENC 36.0K
- Earning Date
- ACRS 05-06-2025
- GENC 05-09-2025
- Dividend Yield
- ACRS N/A
- GENC N/A
- EPS Growth
- ACRS N/A
- GENC 35.02
- EPS
- ACRS N/A
- GENC 1.11
- Revenue
- ACRS $18,720,000.00
- GENC $113,116,000.00
- Revenue This Year
- ACRS N/A
- GENC N/A
- Revenue Next Year
- ACRS N/A
- GENC N/A
- P/E Ratio
- ACRS N/A
- GENC $11.36
- Revenue Growth
- ACRS N/A
- GENC 5.44
- 52 Week Low
- ACRS $0.95
- GENC $11.75
- 52 Week High
- ACRS $5.17
- GENC $24.88
- Technical
- Relative Strength Index (RSI)
- ACRS 28.64
- GENC 36.65
- Support Level
- ACRS $1.57
- GENC $12.40
- Resistance Level
- ACRS $1.78
- GENC $13.11
- Average True Range (ATR)
- ACRS 0.10
- GENC 0.73
- MACD
- ACRS 0.02
- GENC -0.01
- Stochastic Oscillator
- ACRS 17.74
- GENC 2.25
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.